Novel b0at1 inhibitor
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsHidenori TODOROKI, Takafumi SAITO, Kazunari SHIMOOKA, Takahiro YAMADA, Kenji FUKUNAGA, Rentaro KANNO, Takuya IMAZU
Life of this patent
Estimating the term…
Loading patent…
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsHidenori TODOROKI, Takafumi SAITO, Kazunari SHIMOOKA, Takahiro YAMADA, Kenji FUKUNAGA, Rentaro KANNO, Takuya IMAZU
Estimating the term…
The present invention aims to provide a novel B0AT1 inhibitor. A compound represented by the following formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof. Also, the present invention provides a B0AT1 inhibitor containing the aforementioned compound, and a drug containing the aforementioned compound for the prophylaxis and/or treatment of amino acid metabolism disorders such as phenylketonuria, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric academia, and the like.
A method for inhibiting B0AT1 comprising administering an effective amount of a compound represented by the formula (I):
A compound represented by the formula (I′):
A compound represented by the formula (I″):
Dependencies are inferred from the claim text.